Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$1.95 -7.1%	$3.07	$1.91 ▼ $5.64	$139.70M	1.28	1.12 million shs	2.73 million shs
FBRX Forte Biosciences	$11.05 +0.5%	$11.12	$4.11 ▼ $28.68	$136.76M	2.69	78,061 shs	59,219 shs
PPCB Propanc Biopharma	$2.73 -9.6%	$5.36	$1.25 ▼ $145.46	$31.70M	2.67	863,697 shs	426,097 shs
ZURA Zura Bio	$2.02 -1.0%	$1.56	$0.97 ▼ $5.07	$132.64M	-0.02	358,078 shs	160,363 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	0.00%	-4.98%	-20.45%	-40.17%	-9.09%
FBRX Forte Biosciences	0.00%	-2.74%	+14.46%	+15.18%	+39.24%
PPCB Propanc Biopharma	0.00%	-10.39%	-68.54%	-1.31%	+754,900.00%
ZURA Zura Bio	0.00%	-0.49%	+36.00%	+90.65%	-50.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	2.6505 of 5 stars	3.4	3.0	0.0	0.0	2.7	1.7	0.6
FBRX Forte Biosciences	3.4467 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.6
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	3.1727 of 5 stars	3.5	3.0	0.0	0.0	2.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	417.95% Upside
FBRX Forte Biosciences	3.00	Buy	$68.00	515.38% Upside
PPCB Propanc Biopharma	0.00	N/A	N/A	N/A
ZURA Zura Bio	3.00	Buy	$14.00	593.07% Upside

Current Analyst Ratings Breakdown

Latest PPCB, FBRX, CRDF, and ZURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
8/18/2025	FBRX Forte Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/18/2025	FBRX Forte Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/15/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
8/15/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $16.00
8/15/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	190.78	N/A	N/A	$1.86 per share	1.05
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	($493.34) per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	11/6/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-85.38%	-72.34%	11/13/2025 (Estimated)
PPCB Propanc Biopharma	-$1.82M	N/A	0.00	∞	N/A	N/A	-3,652.66%	-971.09%	N/A
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-49.11%	-40.06%	11/6/2025 (Estimated)

Latest PPCB, FBRX, CRDF, and ZURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FBRX Forte Biosciences	-$1.21	-$0.96	+$0.25	-$0.96	N/A	N/A
8/14/2025	Q2 2025	ZURA Zura Bio	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	4.42	4.42
FBRX Forte Biosciences	N/A	11.74	11.74
PPCB Propanc Biopharma	0.01	2.24	2.24
ZURA Zura Bio	N/A	8.40	8.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
FBRX Forte Biosciences	77.63%
PPCB Propanc Biopharma	N/A
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
FBRX Forte Biosciences	5.90%
PPCB Propanc Biopharma	0.10%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FBRX Forte Biosciences	5	12.43 million	11.70 million	Optionable
PPCB Propanc Biopharma	1	11.61 million	19,000	Not Optionable
ZURA Zura Bio	3	65.02 million	50.65 million	Optionable

PPCB, FBRX, CRDF, and ZURA Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Buy" from Analysts

September 2 at 3:20 AM | marketbeat.com

FY2025 EPS Estimates for Zura Bio Boosted by HC Wainwright

August 23, 2025 | marketbeat.com

FY2025 EPS Estimates for Zura Bio Lifted by HC Wainwright

August 23, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Given New $2.00 Price Target at HC Wainwright

August 21, 2025 | marketbeat.com

Zura Bio price target lowered to $2 from $3 at H.C. Wainwright

August 19, 2025 | msn.com

Q1 Earnings Estimate for Zura Bio Issued By Leerink Partnrs

August 19, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at Oppenheimer

August 17, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital

August 17, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 16, 2025 | marketbeat.com

Zura Bio price target lowered to $16 from $17 at Oppenheimer

August 15, 2025 | msn.com

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 14, 2025 | businesswire.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

August 7, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

August 6, 2025 | marketbeat.com

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31, 2025 | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB, FBRX, CRDF, and ZURA Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$1.95 -0.15 (-7.14%)

Closing price 04:00 PM Eastern

Extended Trading

$1.98 +0.03 (+1.74%)

As of 07:56 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Forte Biosciences NASDAQ:FBRX

$11.05 +0.05 (+0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$11.04 -0.01 (-0.05%)

As of 04:04 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Propanc Biopharma OTCMKTS:PPCB

$2.73 -0.29 (-9.60%)

As of 04:00 PM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Zura Bio NASDAQ:ZURA

$2.02 -0.02 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+0.99%)

As of 06:57 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time